Pluri (PLUR) AI Stock Analysis

• Market Cap: $42.77M
• Dividend Yield: N/A
• Average Volume (3M): 12.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: 203.23%
• EPS Growth: 13.57%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 7,832,601
• 10 Day Avg. Volume: 16,101
• 30 Day Avg. Volume: 12,833
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 41.68
• Enterprise Value/Gross Profit: 90.17
• Enterprise Value/Ebitda: -2.18
• 1Y Price Target: $12.00
• Price Target Upside: 119.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $5.00 ▼(-8.42% Downside)

Pluri's overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and high leverage. While technical indicators suggest some positive momentum, the negative valuation metrics and lack of profitability weigh heavily on the score. The recent corporate event of regaining Nasdaq compliance is positive but does not significantly alter the overall risk profile.

Pluri Business Overview & Revenue Model

Company Description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

How the Company Makes Money

Pluri generates revenue primarily through the sale of its software solutions and platform subscriptions. The company offers various pricing tiers, enabling it to cater to both small businesses and large enterprises. Additionally, Pluri forms strategic partnerships with other technology providers to enhance its product offerings and expand its market reach, which also contributes to its revenue streams. The company's earnings are further supported by consulting and support services provided to its clients, ensuring successful implementation and ongoing utilization of its software solutions.

Pluri Financial Statement Overview

Summary

Pluri faces significant financial challenges, with ongoing losses and high leverage. While revenue growth is a positive sign, the company's profitability and cash flow issues pose substantial risks. The high debt levels and minimal equity raise concerns about financial stability and the ability to sustain operations without additional financing.

Income Statement

Pluri's income statement shows a consistent increase in revenue over the years, with a notable growth rate of 13.57% from 2023 to 2024. However, the company continues to incur significant losses, as evidenced by negative EBIT and net income margins. The gross profit margin is high at 98.77% for 2024, but this is overshadowed by the substantial operating losses, indicating challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a precarious financial position, with a very high debt-to-equity ratio due to minimal stockholders' equity. The equity ratio has drastically declined to 0.24% in 2024, reflecting high leverage and potential solvency risks. Return on equity is negative, further indicating financial instability and challenges in generating returns for shareholders.

Cash Flow

Pluri's cash flow statement highlights ongoing cash flow challenges, with negative operating and free cash flows. The free cash flow growth rate improved slightly from 2023 to 2024, but remains negative, indicating continued cash burn. The operating cash flow to net income ratio is positive, suggesting some efficiency in managing cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.03M	326.00K	287.00K	234.00K	0.00	23.00K
Gross Profit	478.00K	322.00K	278.00K	-819.00K	-1.37M	-1.55M
EBITDA	-19.76M	-20.23M	-27.68M	-39.43M	-48.42M	-27.91M
Net Income	-20.90M	-20.89M	-28.32M	-41.24M	-49.87M	-29.15M
Balance Sheet
Total Assets	37.41M	39.53M	50.80M	68.06M	93.54M	65.53M
Cash, Cash Equivalents and Short-Term Investments	26.27M	30.24M	40.17M	55.02M	64.95M	45.78M
Total Debt	31.19M	29.61M	29.91M	28.80M	24.58M	1.58M
Total Liabilities	36.92M	34.11M	35.50M	35.88M	36.39M	9.43M
Stockholders Equity	-4.47M	96.00K	13.36M	30.04M	57.15M	56.10M
Cash Flow
Free Cash Flow	-18.21M	-18.34M	-23.12M	-36.78M	-31.28M	-26.64M
Operating Cash Flow	-17.31M	-18.02M	-22.86M	-36.50M	-30.91M	-26.37M
Investing Cash Flow	193.00K	10.58M	9.70M	11.78M	-7.26M	-30.46M
Financing Cash Flow	18.81M	8.84M	8.02M	7.50M	61.40M	60.87M

Pluri Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Positive. The current price of 5.46 is above the 20-day moving average (MA) of 5.01, above the 50-day MA of 5.02, and above the 200-day MA of 4.74, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 57.02 is Neutral, neither overbought nor oversold. The STOCH value of 77.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLNN	54 Neutral	$53.25M	―	-1738.36%	―	-35.29%	45.18%
Sector *	51 Neutral	$7.78B	-0.06	-40.08%	2.29%	21.32%	-1.82%
PLUR	49 Neutral	$42.77M	―	-1205.58%	―	203.23%	13.57%
DARE	46 Neutral	$28.04M	―	597.53%	―	88.13%	92.45%
GDTC	41 Neutral	$23.14M	―	-24.97%	―	―	38.80%
TPST	39 Underperform	$44.51M	―	-322.57%	―	―	3.39%
NRSN	30 Underperform	$28.12M	―	-2880.11%	―	―	31.09%

Pluri Corporate Events

Pluri’s 2025 Annual Meeting Decisions Announced

On June 30, 2025, Pluri held its 2025 Annual Meeting where shareholders voted on several proposals. Key decisions included the election of directors, ratification of the accounting firm Kesselman & Kesselman, approval of the 2016 Equity Compensation Plan, and the determination that future advisory votes on executive compensation will occur every two years. Additionally, the approval of the exercise of warrants related to a private placement offering was confirmed, excluding shares owned by Mr. Alexandre Weinstein.

The most recent analyst rating on (PLUR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Pluri Regains Nasdaq Compliance Before Deadline

Pluri Inc. received a deficiency letter from Nasdaq on November 25, 2024, for not meeting the stockholders’ equity requirement or alternative listing standards. After submitting a compliance plan, Nasdaq granted an extension until May 24, 2025. By May 7, 2025, Pluri regained compliance by maintaining a market value of $35 million for 10 consecutive days, ensuring its continued listing on The Nasdaq Capital Market.